Marcelo Bigal Net Worth

The estimated Net Worth of Marcelo Bigal is at least 132 千$ dollars as of 16 August 2024. Marcelo Bigal owns over 1,512 units of Pacira BioSciences Inc stock worth over 131,846$ and over the last few years Marcelo sold PCRX stock worth over 0$.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Marcelo Bigal PCRX stock SEC Form 4 insiders trading

Marcelo has made over 2 trades of the Pacira BioSciences Inc stock since 2024, according to the Form 4 filled with the SEC. Most recently Marcelo bought 1,512 units of PCRX stock worth 20,034$ on 16 August 2024.

The largest trade Marcelo's ever made was buying 3,400 units of Pacira BioSciences Inc stock on 12 August 2024 worth over 40,834$. On average, Marcelo trades about 1,228 units every 1 days since 2023. As of 16 August 2024 Marcelo still owns at least 10,142 units of Pacira BioSciences Inc stock.

You can see the complete history of Marcelo Bigal stock trades at the bottom of the page.

What's Marcelo Bigal's mailing address?

Marcelo's mailing address filed with the SEC is C/O PACIRA BIOSCIENCES, INC., 5401 WEST KENNEDY BOULEVARD, SUITE 890, TAMPA, FL, 33609.

Insiders trading at Pacira BioSciences Inc

Over the last 14 years, insiders at Pacira BioSciences Inc have traded over 321,391,130$ worth of Pacira BioSciences Inc stock and bought 2,075,444 units worth 15,133,188$ . The most active insiders traders include Advisors Llc Orbi Med Capit...、Carl L Gordon、Andreas Wicki. On average, Pacira BioSciences Inc executives and independent directors trade stock every 13 days with the average trade being worth of 491,036$. The most recent stock trade was executed by Marcelo Bigal on 16 August 2024, trading 1,512 units of PCRX stock currently worth 20,034$.

What does Pacira BioSciences Inc do?

pacira pharmaceuticals, inc. (nasdaq: pcrx) is an emerging specialty pharmaceutical company focused on the clinical and commercial development of new products that meet the needs of acute care practitioners and their patients. the company's current emphasis is the development of non-opioid products for postsurgical pain control, and its lead product, exparel® (bupivacaine liposome injectable suspension), was commercially launched in the united states in april 2012. exparel and two other products have utilized the pacira proprietary product delivery technology depofoam®, a unique platform that encapsulates drugs without altering their molecular structure and then releases them over a desired period of time.

Complete history of Marcelo Bigal stock trades at Pacira BioSciences Inc

Pacira BioSciences Inc executives and stock owners

Pacira BioSciences Inc executives and other stock owners filed with the SEC include:

• David Stack,
  Chairman of the Board, Chief Executive Officer
• Max Reinhardt,
  President
• Dennis McLoughlin,
  Chief Commercial Officer
• Kristen Williams,
  Chief Administrative Officer, Secretary
• Roy Winston,
  Chief Clinical Officer
• David M. Stack,
  Chairman & CEO
• Charles Reinhart,
  Chief Financial Officer
• Dr. Roy Winston M.D.,
  Chief Medical Officer
• Christopher Christie,
  Director
• Max Reinhardt,
  Pres of Rest of World
• Dr. Jonathan Slonin M.D.,
  Chief Clinical Officer
• Kristen Williams,
  Chief Admin. Officer & Sec.
• Charles A. Reinhart III, CPA, M.B.A.,
  Chief Financial Officer
• Paul Hastings,
  Lead Independent Director
• Laura Brege,
  Independent Director
• John Longenecker,
  Independent Director
• Mark Kronenfeld,
  Independent Director
• Yvonne Greenstreet,
  Independent Director
• Mark Froimson,
  Independent Director
• Gary Pace,
  Independent Director
• Susan Mesco,
  IR Contact Officer
• Andreas Wicki,
  Independent Director
• Charles Laranjeira,
  Chief Technical Officer
• Kristen Williams J.D.,
  Chief Admin. Officer & Sec.
• Daryl Gaugler,
  Chief Operating Officer
• Robert J. Weiland,
  Sr. VP of Alliance Management
• Richard Kahr,
  VP of HR
• Charles Laranjeira,
  Chief Technical Officer
• Lauren Bullaro Riker,
  Principal Accounting Officer & VP of Fin.
• Dennis L Winger,
  Director
• Scott Braunstein,
  SVP, Strategy & Corp. Dev.
• Robert J. Weiland,
  Chief Commercial Officer
• Richard Scranton,
  Chief Scientific Officer
• James B Jones,
  SVP & Chief Medical Officer
• James S Scibetta,
  Chief Financial Officer
• Gary Patou,
  Director
• Taunia Markvicka,
  Vice President, Commercial
• Advisors Llc Orbi Med Capit...,
  
• Venture Partners Vi Lp Sand...,
  
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Bio Ventures Iv Qp Lp Scopa...,
  
• Carl L Gordon,
  Director
• Bio Ventures Iv Qp Lpmpm Bi...,
  
• Venture Partners Vi Lp Sand...,
  
• Luke Evnin,
  Director
• John Pratt,
  General Manager, San Diego
• Vaughn Mgadicke Ansbert Kai...,
  
• Bioventures Cayman Ltd Hbm,
  10% owner
• Fred A Middleton,
  Director
• Venture Partners Vi Lp Sand...,
  
• Venture Partners Vi Lp Sand...,
  
• Abraham Ceesay,
  Director
• Alethia Young,
  Director
• Marcelo Bigal,
  Director
• Michael J. Yang,
  Director
• Donald C. Manning,
  Chief Medical Officer
• Lauren Riker,
  Senior Vice President, Finance
• Anthony Molloy,
  Chief Lgl & Compliance Officer
• Daryl Gaugler,
  Chief Operating Officer
• Ronald J. Jr. Ellis,
  Chief Strategy Officer
• Jonathan Slonin,
  Chief Medical Officer
• Frank D. Lee,
  Chief Executive Officer